Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19176410 | 0.83 | PTGS2 (0.44) | PTGS2MAPTKMT2ALMNATDP1 | |
| SCHEMBL7531918 | 0.81 | MAPT (0.59) | MAPTKMT2ALMNATDP1L3MBTL1 | |
| SCHEMBL5663443 | 0.81 | KMT2A (0.51) | MAPTKMT2ALMNAL3MBTL1KDM4E | |
| SCHEMBL13754318 | 0.80 | APP (0.49) | PTGS2KMT2ALMNAKDM4EALDH1A1 | |
| SCHEMBL7526020 | 0.79 | SMN1; SMN2 (0.45) | MAPTKMT2ALMNATDP1L3MBTL1 | |
| SCHEMBL7529150 | 0.79 | KMT2A (0.55) | MAPTKMT2ALMNATDP1L3MBTL1 | |
| SCHEMBL7525424 | 0.78 | MAPT (0.53) | MAPTKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL14452374 | 0.77 | BRD4 (0.50) | MAPTKMT2ALMNAALDH1A1MEN1 | |
| SCHEMBL12963035 | 0.77 | ALDH1A1 (0.42) | MAPTKMT2ALMNAL3MBTL1KDM4E | |
| SCHEMBL7531647 | 0.76 | DHFR (0.46) | MAPTKMT2ALMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137740-A1 | Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them | FONTAINE EVELYNE (FR) | 2002-09-26 | — | — | US | disclosed |
| EP-0934290-B1 | AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2002-04-17 | — | — | EP | disclosed |
| US-6344470-B1 | Aminothiazole derivatives, method of preparation and pharmaceutical compositions containing same | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| EP-0934290-A1 | AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015543-A1 | AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137740-A1 | Aminothiazole derivatives, process for preparing them and pharmaceutical compositions containing them | CRHR1, ADRA1D, ADRB1 | PTGS2 1084/4885MAPT 1420/4885KMT2A 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.